The Use of Cyclosporine in Pediatric Recipients of Renal Transplants
The superior results of cyclosporine (CsA) immunosuppression in combination with prednisone (Pred), which was initiated at the University of Texas Medical School at Houston for adult patients in August, 1980, compared to the previous azathioprine-Pred combination, led to application of this regimen to pediatric recipients one year later (1). On the one hand, there were the concerns of carcinogenicity, and particularly in a pediatric population that CsA-induced nephrotoxicity would produce chronic renal dysfunction sufficient to prevent post-transplant growth and development. On the other hand, the possible benefit of improved graft survival and reduced numbers of rejection episodes decreasing the cumulative steroid dose proffered better rehabilitation. The present communication describes our four year experience with the CsA-Pred regimen in 34 children aged 1.5 to 16 years.
KeywordsGraft Survival Allograft Rejection Rejection Episode Pediatric Recipient Texas Medical School
Unable to display preview. Download preview PDF.
- 1.Kahan, B.D., Van Buren, C., Flechner, S., Payne, W.D., Boileau, M., and Kerman, R.: Cyclosporine immunosuppression mitigates immunologie risk factors in renal allotransplantation. Transplant. Proc. 15(4): 2469–2478, 1983.Google Scholar
- 5.Conley, S.B., Brewer, E., Flechner, S., Van Buren, C.T., and Kahan, B.D.: Renal transplantation using cyclosporine in pediatric patients 3 to 17 years old. Transplant. Proc. 15(4): 2528, 1983.Google Scholar
- 6.Flechner, S.M., Conley, S.B., Rose, G., Van Buren, C., Kerman, R., Lorber, M., and Kahan, B.D.: Cyclosporine and prednisone immunosuppression in pediatric recipients of renal allografts. Actua Sandoz, 1986: in press.Google Scholar